Pedro Berraondo

Dr. Pedro Berraondo

Program of Immunology and Immunotherapy, CIMA, University of Navarra, Pamplona, Navarre, Spain
orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 November 2018 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
Pedro BerraondoPedro Berraondo
Pedro Berraondo
MSMiguel F. Sanmamed
Miguel F. Sanmamed
MOMaría C Ochoa
María C Ochoa
IEInaki Etxeberria
Inaki Etxeberria
MAMaria A. Aznar
Maria A. Aznar
IMIGNACIO MELERO
IGNACIO MELERO
Cytokines are soluble proteins that mediate cell-to-cell communication. Based on the discovery of the potent anti-tumour activities of several pro-inflammatory cytokines in animal models, clinical research led to the approval of recombinant interferon-alpha and interleukin-2 for the treatment of several malignancies, even if efficacy was only modest. These early milestones in immunotherapy have been followed by the recent addition to clinical practice of antibodies that inhibit immune checkpoints, as well as chimeric antigen receptor T cells. A renewed interest in the anti-tumour properties of cytokines has led to an exponential increase in the number of clinical trials that explore the safety and efficacy of cytokine-based drugs, not only as single agents, but also in combination with other immunomodulatory drugs. These second-generation drugs under clinical development include known molecules with novel mechanisms of action, new targets, and fusion proteins that increase half-life and target cytokine activity to the tumour microenvironment or to the desired effector immune cells. In addition, the detrimental activity of immunosuppressive cytokines can be blocked by antagonistic antibodies, small molecules, cytokine traps or siRNAs. In this review, we provide an overview of the novel trends in the cytokine immunotherapy field that are yielding therapeutic agents for clinical trials.

1 May 2020 in Immunity
Verified
Journal Article
Closed access
Alvaro TeijeiraAlvaro Teijeira
Alvaro Teijeira
SGSaray Garasa
Saray Garasa
MGMaría Gato
María Gato
Carlos AlfaroCarlos Alfaro
Carlos Alfaro
IMItziar Migueliz
Itziar Migueliz
IMIGNACIO MELERO
IGNACIO MELERO

11 February 2019 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
KSKurt A. Schalper
Kurt A. Schalper
MRMaria Rodriguez-Ruiz
Maria Rodriguez-Ruiz
RDRicardo Diez-Valle
Ricardo Diez-Valle
ALAlvaro Lopez-Janeiro
Alvaro Lopez-Janeiro
APAngelo Porciuncula
Angelo Porciuncula
IMIGNACIO MELERO
IGNACIO MELERO

1 May 2019 in Nature
Verified
Journal Article
Open access
PDF file
EPElisabeth Perez-Ruiz
Elisabeth Perez-Ruiz
LMLuna Minute
Luna Minute
IOItziar Otano
Itziar Otano
MAMaite Alvarez
Maite Alvarez
MOMaria Carmen Ochoa
Maria Carmen Ochoa
IMIGNACIO MELERO
IGNACIO MELERO
Combined PD-1 and CTLA-4-targeted immunotherapy with nivolumab and ipilimumab is effective against melanoma, renal cell carcinoma and non-small-cell lung cancer1,2,3. However, this comes at the cost of frequent, serious immune-related adverse events, necessitating a reduction in the recommended dose of ipilimumab that is given to patients4. In mice, co-treatment with surrogate anti-PD-1 and anti-CTLA-4 monoclonal antibodies is effective in transplantable cancer models, but also exacerbates autoimmune colitis. Here we show that treating mice with clinically available TNF inhibitors concomitantly with combined CTLA-4 and PD-1 immunotherapy ameliorates colitis and, in addition, improves anti-tumour efficacy. Notably, TNF is upregulated in the intestine of patients suffering from colitis after dual ipilimumab and nivolumab treatment. We created a model in which Rag2−/−Il2rg−/− mice were adoptively transferred with human peripheral blood mononuclear cells, causing graft-versus-host disease that was further exacerbated by ipilimumab and nivolumab treatment. When human colon cancer cells were xenografted into these mice, prophylactic blockade of human TNF improved colitis and hepatitis in xenografted mice, and moreover, immunotherapeutic control of xenografted tumours was retained. Our results provide clinically feasible strategies to dissociate efficacy and toxicity in the use of combined immune checkpoint blockade for cancer immunotherapy.

31 July 2016 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
Carlos AlfaroCarlos Alfaro
Carlos Alfaro
Alvaro TeijeiraAlvaro Teijeira
Alvaro Teijeira
COCarmen Oñate
Carmen Oñate
GPGuiomar Pérez
Guiomar Pérez
MSMiguel F. Sanmamed
Miguel F. Sanmamed
IMIGNACIO MELERO
IGNACIO MELERO
Purpose: Myeloid-derived suppressor cells (MDSC) are considered an important T-cell immunosuppressive component in cancer-bearing hosts. The factors that attract these cells to the tumor microenvironment are poorly understood. IL8 (CXCL8) is a potent chemotactic factor for neutrophils and monocytes. Experimental Design: MDSC were characterized and sorted by multicolor flow cytometry on ficoll-gradient isolated blood leucokytes from healthy volunteers (n = 10) and advanced cancer patients (n = 28). In chemotaxis assays, sorted granulocytic and monocytic MDSC were tested in response to recombinant IL8, IL8 derived from cancer cell lines, and patient sera. Neutrophil extracellular traps (NETs) formation was assessed by confocal microscopy, fluorimetry, and time-lapse fluorescence confocal microscopy on short-term MDSC cultures. Results: IL8 chemoattracts both granulocytic (GrMDSC) and monocytic (MoMDSC) human MDSC. Monocytic but not granulocytic MDSC exerted a suppressor activity on the proliferation of autologous T cells isolated from the circulation of cancer patients. IL8 did not modify the T-cell suppressor activity of human MDSC. However, IL8 induced the formation of NETs in the GrMDSC subset. Conclusions: IL8 derived from tumors contributes to the chemotactic recruitment of MDSC and to their functional control. Clin Cancer Res; 22(15); 3924–36. ©2016 AACR.

29 December 2020 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
Alvaro TeijeiraAlvaro Teijeira
Alvaro Teijeira
SGSaray Garasa
Saray Garasa
MOMaria C. Ochoa
Maria C. Ochoa
MVMaría Villalba
María Villalba
IOIrene Olivera
Irene Olivera
IMIGNACIO MELERO
IGNACIO MELERO
One of the most important mechanisms by which cancer fosters its own development is the generation of an immune microenvironment that inhibits or impairs antitumor immune responses. A cancer permissive immune microenvironment is present in a large proportion of the patients with cancer who do not respond to immunotherapy approaches intended to trigger preexisting antitumor immune responses, for instance, immune checkpoint blockade. High circulating levels of IL8 in patients with cancer quite accurately predict those who will not benefit from checkpoint-based immunotherapy. IL8 has been reported to favor cancer progression and metastases via different mechanisms, including proangiogenesis and the maintenance of cancer stem cells, but its ability to attract and functionally modulate neutrophils and macrophages is arguably one of the most important factors. IL8 does not only recruit neutrophils to tumor lesions, but also triggers the extrusion of neutrophil extracellular traps (NET). The relevance and mechanisms underlying the contribution of both neutrophils and NETs to cancer development and progression are starting to be uncovered and include both direct effects on cancer cells and changes in the tumor microenvironment, such as facilitating metastasis, awakening micrometastases from dormancy, and facilitating escape from cytotoxic immune cells. Blockade of IL8 or its receptors (CXCR1 and CXCR2) is being pursued in drug development, and clinical trials alone or in combination with anti-PD-L1 checkpoint inhibitors are already ongoing.